A subset analysis of efficacy and safety outcomes from phase 3 clinical studies of ixekizumab for the treatment of patients with severe plaque psoriasis

Spelman, Lynda; Rubel, Diana; Brnabic, Alan; Burkhardt, Nicole Y.; Riedl, Elisabeth; Foley, Peter

doi:10.1080/09546634.2020.1752888

Cited by 3 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Biologics and small molecules, as previously suggested by both real‐life registries and trials, increased airway infections 2,6 and this detrimental effect is still valid in COVID‐19. However, their inhibition of pro‐inflammatory cytokines detrimental in the viral phase, seems to be fundamentally beneficial in the hyperinflammatory phase protecting PsO patients to the progression to the extrapulmonary manifestations and death 5 …”

Section: Discussionmentioning

confidence: 84%

Biologics increase the risk of SARS ‐ CoV ‐2 infection and hospitalization, but not ICU admission and death: Real‐life data from a large cohort during red‐zone declaration

Damiani

Pacifico

Bragazzi

et al. 2020

Dermatologic Therapy

104

View full text Add to dashboard Cite

During COVID-19 outbreak there are discordant opinions toward the impact on biologics in psoriatic (PsO) patients. Thus we performed a single-center case-control study in Lombardia, the Italian region with the higher number of COVID-19 confirmed cases.We enrolled 1193 PsO patients treated with biologics and small molecules and we used the entire Lombardia population as controls. Notably, 17 PsO patients COVID-19 confirmed were quarantined at home and five hospitalized, no PsO patients were admitted to intensive care unit (ICU) or died. With respect to the general population of Lombardy, patients on biologics were at higher risk to test positive for 3.43 [95% confidence interval (CI) 2.25-5.73], P < .0001), to be self-quarantined at home (OR 9.05 [95% CI 5.61-14.61], P < .0001) and hospitalized (OR 3.59 [95% CI 1.49-8.63], P = .0044), however, not increased risk of ICU admission or death were found. PsO patients on biologics should be carefully monitored with telemedicine during COVID-19 outbreak and early treated at home to limit hospital overwhelm.

show abstract

Section: Discussionmentioning

confidence: 84%

Biologics increase the risk of SARS ‐ CoV ‐2 infection and hospitalization, but not ICU admission and death: Real‐life data from a large cohort during red‐zone declaration

Damiani

Pacifico

Bragazzi

et al. 2020

Dermatologic Therapy

104

View full text Add to dashboard Cite

show abstract

“…Um eine schnelle Remission zu erreichen, haben wir uns für Ixekizumab entschieden, einen hochaffinen monoklonalen Antikörper, der selektiv auf IL-17A abzielt und der für seine schnelle Wirkung bei Psoriasis vulgaris bekannt ist [5]. Das Ansprechen war beträchtlich, und nach nur 2 Injektionen zum Zeitpunkt 0 beobachteten wir eine vollständige Auflösung der aktiven Hautläsion (Abb 1b).…”

Section: Fallbeschreibungunclassified

Schwere generalisierte pustulöse Psoriasis erfolgreich mit Ixekizumab behandelt: Ein Fallbericht

Burlando¹,

Salvi²,

Paravisi³

et al. 2023

Kompass Dermatol

View full text Add to dashboard Cite

Die generalisierte pustuläre Psoriasis (GPP) ist eine schwere und potenziell lebensbedrohliche Art der Psoriasis. Wir stellen den Fall eines Patienten mit schwerer GPP vor, die zunächst erfolglos mit Cyclosporin behandelt wurde. Wir haben uns für die Behandlung des Patienten mit Ixekizumab entschieden, einem Anti-IL-17-Antikörper, der für seine schnelle Wirkung bei Psoriasis vulgaris bekannt ist und auch bei GPP als wirksam beschrieben wurde. Der Zustand des Patienten verbesserte sich schnell, mit Auflösung der aktiven Läsionen nach der ersten Verabreichung. Die Behandlung wird seit 2 Jahren ohne unerwünschte Ereignisse und mit anhaltender Krankheitsüberwachung fortgesetzt. Ixekizumab könnte als sichere und effektive Option bei Patienten mit GPP angesehen werden.

show abstract

“…Aiming to achieve remission quickly, we decided to start ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A, known for its rapid action in psoriasis vulgaris [ 5 ]. The response was dramatic, and after only two injections at time 0, we observed complete resolution of the active skin lesion (shown in Fig.…”

Section: Case Reportmentioning

confidence: 99%

Severe Generalized Pustular Psoriasis Successfully Treated with Ixekizumab: A Case Report

Burlando¹,

Salvi²,

Paravisi³

et al. 2022

Case Rep Dermatol

View full text Add to dashboard Cite

Generalized pustular psoriasis (GPP) is a severe and potentially life-threatening type of psoriasis. We present the case of a patient with severe GPP, at first unsuccessfully treated with cyclosporine. We chose to treat the patient with ixekizumab, an anti-IL-17 antibody known for its rapid action in psoriasis vulgaris, that has also been reported as effective in GPP. The patient improved rapidly, with resolution of the active lesions after the first administration. The treatment has been continued for 2 years, with no adverse events and sustained disease control. Ixekizumab could be considered a safe and effective option in patients with GPP.

show abstract

A subset analysis of efficacy and safety outcomes from phase 3 clinical studies of ixekizumab for the treatment of patients with severe plaque psoriasis

Abstract: 2020): A subset analysis of efficacy and safety outcomes from phase 3 clinical studies of ixekizumab for the treatment of patients with severe plaque psoriasis, Journal of Dermatological Treatment,

Cited by 3 publications

References 23 publications

Biologics increase the risk of SARS ‐ CoV ‐2 infection and hospitalization, but not ICU admission and death: Real‐life data from a large cohort during red‐zone declaration

Biologics increase the risk of SARS ‐ CoV ‐2 infection and hospitalization, but not ICU admission and death: Real‐life data from a large cohort during red‐zone declaration

Schwere generalisierte pustulöse Psoriasis erfolgreich mit Ixekizumab behandelt: Ein Fallbericht

Severe Generalized Pustular Psoriasis Successfully Treated with Ixekizumab: A Case Report

Contact Info

Product

Resources

About